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Objective: Pulmonary fibrosis is associated with an increased risk of lung cancer and
outcome of surgical resection in this setting is unknown.
Methods: We studied 22 patients (24 operations) with pulmonary fibrosis and
non-small cell lung cancer treated between 1991 and 2000 (study group) and
compared outcome with 951 other patients (964 operations) treated for non-small
cell lung cancer over the same period (control patients).
Results: The two groups did not differ significantly in age (68 vs 65 years), smoking
history (86% vs 95% smokers), forced expiratory volume in 1 second (2.5 L/min vs
2.3 L/min) or forced vital capacity (3.2 L vs 3.7 L), but patients with pulmonary
fibrosis were more likely to be male (72% vs 58%, P .05). The operative mortality
was higher in patients with pulmonary fibrosis than in control patients (17% vs
3.1%, P  .01) and there was a higher procedure-specific mortality in pulmonary
fibrosis for pneumonectomy (33% vs 5.1%, P  .01) and lobectomy (12% vs 2.6%,
P  .01). Patients with pulmonary fibrosis had a higher incidence of postoperative
lung injury, (21% vs 3.7%, P  .01) and a longer mean hospital stay (17 vs 9 days,
P .05). In patients with pulmonary fibrosis, the actuarial 3-year survival was 54%.
There were 11 deaths in the study group, 4 postoperatively (all acute respiratory
distress syndrome) and 7 late deaths (metastatic disease, n  2; progressive
pulmonary fibrosis, n  5). Median follow-up (to death or last review) was 13
months (range, 0-120 months). Five patients developed postoperative acute respi-
ratory distress syndrome and in 4 of these patients this proved to be fatal. Postop-
erative acute respiratory distress syndrome was associated with lower preoperative
total lung carbon monoxide diffusion capacity (median, 58% vs 70%, P  .03) and
lower preoperative carbon monoxide diffusion capacity corrected for alveolar vol-
ume (median, 48% vs 58%, P  .05) and a higher preoperative composite physi-
ological index (median, 44 vs 33, P .008). None of the preoperative lung function
parameters or operative finding were predictors of late death.
Conclusion: Patients with pulmonary fibrosis undergoing pulmonary resection for
non-small cell lung cancer have increased postoperative morbidity and mortality,
but an important subgroup has a good long-term outcome. Postoperative acute
respiratory distress syndrome is associated with low preoperative gas transfer and a
high composite physiological index. Resection of non-small cell lung cancer is
appropriate in pulmonary fibrosis, provided that the level of functional impairment
is carefully factored into patient selection.
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Pulmonary fibrosis, also known as fibrosingalveolitis or fibrosing interstitial pneumonia,is a progressive diffuse fibrosing lung disease.Pulmonary fibrosis is associated with an in-creased risk of lung cancer, with a relativerisk of 7.0 to 14.0 (compared to the general
population).1,2 Furthermore, lung cancer is the cause of
death in up to 10% of patients with pulmonary fibrosis.1
However, the operative risks of major pulmonary resection
and the long-term survival following resection for non-
small cell lung cancer in patients with pulmonary fibrosis
are unknown.
We reviewed our experience with pulmonary resections
for non–small cell lung cancer in patients with pulmonary
fibrosis, evaluating the relative operative risks compared to
a cohort of patients without pulmonary fibrosis who under-
went pulmonary resection for non-small cell lung cancer
over the same time period. We then assessed the early and
late outcome in patients with pulmonary fibrosis following
pulmonary resection and evaluated the predictors for early
and late outcome.
The noninvasive assessment of disease severity in pul-
monary fibrosis remains debatable. Recently, a composite
physiological index (CPI), constructed against the morpho-
logical severity of the disease in order to calibrate the
quantification of pulmonary fibrosis, has been reported.3
CPI correlates more strongly with the extent of disease on
computed tomography (CT) than any of the individual pul-
monary function tests.
Materials and Methods
A retrospective review of interstitial lung disease and histopathol-
ogy registries at the Royal Brompton Hospital was undertaken to
identify patients with pulmonary fibrosis who underwent pulmo-
nary resection for non-small cell lung cancer between 1991 and
2000. Histology of the all the pulmonary resections for non-small
cell lung cancer was reviewed by a histopathologist specializing in
pulmonary pathology (A.G.N.) to identify all the patients with a
background of pulmonary fibrosis who had undergone pulmonary
resection for non-small cell lung cancer during the study period.
We identified 973 patients who underwent 988 pulmonary resec-
tions for non-small cell lung cancer. After reviewing the histology
of these 988 specimens, 22 patients were identified with evidence
of pulmonary fibrosis (Group I), 2 of who underwent 2 operations
(24 operations). In the remaining 964 specimens (951 operations)
there was no evidence of pulmonary fibrosis (Group II). The
patterns of interstitial pneumonia were classified according to
recently recognized ATS/ERS criteria4 and tumors were classified
according to the WHO/IASLC classification system for lung and
pleural tumors.5
The case records of all patients in both the groups in the study
were reviewed retrospectively, with particular reference to preop-
erative factors likely to predict their outcome. The preoperative CT
scans of all 22 patients with pulmonary fibrosis were reviewed by
a radiologist specializing in pulmonary diseases (D.H.). We sought
to obtain the late outcome only in patients with pulmonary fibrosis,
and these patients were contacted and reviewed in the outpatient’s
clinic to assess their status at follow-up.
Statistical Analysis
Analyses were performed using STATA software (Stata Data
Analysis Software; Computing Resource Centre, Santa Monica,
Calif). Group comparisons were made using Wilcoxon’s rank-sum
test or 2 testing as appropriate. The prognostic values of age,
gender, individual pulmonary function indices, and the CPIs were
evaluated using a proportional hazards model.
Pulmonary Function Tests
The results of preoperative pulmonary function tests were re-
viewed and recorded with particular reference to forced expiratory
volume in 1 second (FEV1), forced vital capacity (FVC), total lung
capacity, residual volume, carbon monoxide diffusion capacity
(DLCO), corrected for hemoglobin concentration, and also for al-
veolar volume (KCO). The results of preoperative arterial blood gas
analysis on air were recorded the alveolar-arterial oxygen gradient
was calculated.
Calculation of CPI
The formula for CPI is 91.0 (0.65% predicted DLCO) (0.53
 % predicted FVC)  (0.34  % predicted FEV1).3
Preoperative and Operative Protocols
Preoperative work up for all patients with lung cancer at our
institution includes full blood count; biochemical profile; chest
radiograph; and a staging CT scan of chest, brain, and abdomen.
Bone scans were performed selectively if indicated. All patients
had routine arterial blood gas measurement and spirometry. All
patients with histologically established pulmonary fibrosis or with
impaired spirometry underwent detailed assessment of lung func-
tion tests, including assessment of gas transfer factors and a
ventilation and perfusion scan to assess the residual pulmonary
function postoperatively. All patients over 50 years of age had an
electrocardiogram. If there was a history of ischemic heart disease,
full cardiological assessment, including a stress test or thallium
scan, was performed before proceeding with the pulmonary resec-
tion. Medications for pulmonary fibrosis, including steroids and
immunosuppressants, were continued throughout the hospitaliza-
tion for pulmonary resection. Using a double-lumen endotracheal
tube, pulmonary resections were performed either through a pos-
tero-lateral or lateral muscle-sparing thoracotomy. For most of the
operative time the lung was deflated to facilitate dissection, how-
ever, while fissures were developed, the lung was temporarily
reinflated. At the end of the procedure, the lung was reinflated and
examined for air leak prior to closure. Systematic lymph node
dissection was performed in all patients undergoing lung resection
for accurate intrathoracic staging of lung cancer.
Results
Clinical Presentation
The demographics, clinical features at presentation and the
preoperative pulmonary function tests of patients in Groups
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I (pulmonary fibrosis) and II (no pulmonary fibrosis) are
summarized in Table 1.
In 12 of 22 (54%) patients in Group I, a diagnosis of
pulmonary fibrosis was histologically established prior to
resection of the non–small cell lung cancer. These 12 pa-
tients were being treated and followed-up at our institution,
during which time they developed additional radiographic
changes suggestive of a pulmonary malignancy. Seven of
12 underwent further investigations, either fiber optic bron-
choscopy or CT-guided biopsy, confirming the presence of
non-small cell lung cancer prior to referral for surgery,
while in the other 5 patients a definitive diagnosis had not
been made prior to thoracotomy. The remaining 10 patients
presented with lung cancer without prior recognition of
pulmonary fibrosis. This was suspected on the preoperative
CT scan but only confirmed histologically after resection.
Among these 10 patients, only 5 had a definitive diagnosis
of non-small cell lung cancer prior to thoracotomy. Three of
22 patients (13.6%) had underlying connective tissue dis-
ease (systemic lupus erythematosus, n  2; systemic scle-
rosis, n  1). However, it is noteworthy that in all 22
patients, pulmonary fibrosis was evident on the preoperative
CT scan.
Pulmonary Resections
In Group I (patients with pulmonary fibrosis), there were 24
pulmonary resections in 22 patients. Of the 24 pulmonary
resections, there were 6 pneumonectomies (1 of which was
completion pneumonectomy), 17 lobectomies, and 1 local-
ized wedge resection. Two patients underwent pulmonary
resections twice. One patient had undergone left upper
lobectomy (pT1 N0 M0 adenocarcinoma) and 3 years later
was noted to have a further opacity in the left lung field; he
subsequently underwent completion pneumonectomy (pT2
N1 M0 squamous cell carcinoma). The second patient had
undergone right upper lobectomy (pT2 N0 M0 bronchioal-
veolar carcinoma) and presented 1 year later with an opacity
in the left upper zone, which was treated by a wedge
resection (pT1 N2 M0 adenocarcinoma) due to presence of
N2 disease at thoracotomy and impaired lung function.
In Group II, pulmonary resection was performed by
pneumonectomy in 215 cases, lobectomy in 695 cases and
lesser resection (segmentectomy or wedge resection) in 54
cases.
The distribution of histological cell types of non-small
cell lung cancer was similar in the 2 groups.
Relative Risks in Patients with Pulmonary Fibrosis
Patients with pulmonary fibrosis had a significantly longer
mean hospital stay (17 vs 9 days, P  .05) and a signifi-
cantly higher incidence of postoperative acute respiratory
distress syndrome/acute lung injury (ARDS/ALI) (21% vs
3.7%, P  .01). In patients with pulmonary fibrosis the
incidence of lung injury ARDS/ALI after pneumonectomy
was 33% compared to 17% after lobectomy (P  .05).
Compared to the control group, the procedure specific
incidence of ARDS/ALI was significantly higher in patients
with pulmonary fibrosis for pneumonectomy (33% vs 6%, P
 .05) and for lobectomy (17% vs 3.1%, P  .05).
Overall postoperative mortality was significantly higher
for patients with pulmonary fibrosis (17% vs 3.1%, P 
.01). Furthermore, procedure-specific outcome also showed
a significantly higher postoperative mortality for pneumo-
nectomy (33% vs 5.1%, P  .01) and lobectomy (12% vs
2.6%, P  .01) in patients with pulmonary fibrosis. There
was no difference in the mortality for minor resection (0%
vs 1.8%, P  NS).
TABLE 1. Preoperative clinical details of all patients un-
dergoing pulmonary resection for NSCLC between 1991 and
2000
Pulmonary
fibrosis
No pulmonary
fibrosis P value
Mean age 68 65 NS
Range 33-87 39-85
Male 16/22 (72) 551/951 (58) .05
Smokers/ex-smokers 19/22 (86) 904/951 (95) NS
Mean smoking history
(pack-years)
62 44 NS
Range 0-110 0-108
Preoperative dyspnea 11/22 (50) *
Established diagnosis of FIP 12/22 (54) N/A
Pulmonary function test
FEV1 (L/min) 2.5 2.6 NS
(% Predicted) (70) (57)
Range 1.4-3.7 1.2-3.9
FVC (L) 3.2 3.5 NS
(% Predicted) (89) (80)
Range 1.6-4.7 1.7-4.9
FEV1/FVC 0.78 0.73 NS
Range 0.5-0.88 0.5-0.81
KCO (mmol · min
1 ·
kPa1 · L1)
0.9 *
(% Predicted) (65)
Range 0.66-1.23
DLCO (mmol · min
1 ·
kPa1)
3.9 *
(% Predicted) (50)
Range 3.0-5.3
Arterial PO2 on air (kPa) 10.5 9.9 NS
Range 8.5-13.1 8.1-13.2
% Oxygen saturation
(% on air)
95 96 NS
% On air 93-98 94-99
NS, Not significant; N/A, not applicable. Pulmonary function data pre-
sented as median values with range. Values in parentheses are percent-
ages.
*Data not available for all patients.
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The outcome of all patients that underwent pulmonary
resection for non-small cell lung cancer between 1991 and
2000 in summarized in Table 2.
Outcome in Patients with Pulmonary Fibrosis
Short-term outcome. Morbidity and mortality are de-
tailed in Table 3. Five patients developed postoperative lung
injury (ARDS/ALI), as defined by the European/American
Consensus Conference,6 and 4 of these patients died in the
early postoperative period with rapidly progressive ARDS.
In terms of procedure-related incidence of ARDS/ALI, 2 of
6 (33%) patients after pneumonectomy and 3 of 17 (17%)
patients after lobectomy developed postoperative ARDS/
ALI. ARDS/ALI was the major postoperative complication.
Postoperative ARDS was associated with lower preop-
erative KCO levels (median, 58% vs 70%; range, 55%-67%
vs 44%-96%; P  .03), lower preoperative DLCO levels
(median, 48% vs 58%; range, 42%-62% vs 39%-78%; P 
.05), and a higher preoperative CPI (median, 44 vs 33;
range, 37-46 vs 14-44; P  .008; Wilcoxon rank sum test).
A preoperative CPI score 40 was associated with a 50%
chance of developing postoperative lung injury. The occur-
rence of ARDS was not related to demographic features,
smoking history, other pulmonary function variables, the
presence of preoperative dyspnea, histologically established
diagnosis of pulmonary fibrosis before pulmonary resection,
the stage of non-small cell lung cancer, or the pattern of
inflammation.
Long-term outcome. In patients with pulmonary fibro-
sis, follow-up ranged from 0.1 to 107 months following
surgery, with a mean follow-up 33 months. The overall
Kaplan-Meier actuarial survival at 3 years was 54% (Figure
1). However, only 11 of 22 (50%) patients were alive when
last interviewed. There were 7 late deaths during follow-up,
including 2 from metastatic lung cancer (both resections
staged at IIIA) and 5 from progressive pulmonary fibrosis
leading to terminal respiratory failure. The 5 patients that
died of progressive pulmonary fibrosis had a median post-
operative survival of 14 months (range, 3-36 months). Late
mortality was not linked to preoperative pulmonary function
indices, the presence of preoperative dyspnea, an histolog-
ically established diagnosis of pulmonary fibrosis prior to
pulmonary resection, extent of resection, stage of the non-
small cell lung cancer, or pattern of inflammation.
Histopathology
Usual interstitial pneumonia (UIP) was present in 16 of 22
patients (15 male and 1 female), with fibrotic nonspecific
interstitial pneumonia (NSIP) in the remaining 6 patients (5
female and 1 male). All 3 patients with connective tissue
disorders had NSIP. All 4 postoperative deaths and 3 of the
5 late non-neoplastic deaths were associated with UIP.
Evaluation of Preoperative CT Scans
In order to exclude the possibility that these histological
changes of pulmonary fibrosis were a localized obstructive
phenomenon related to the tumor and not diffuse parenchy-
mal lung disease, the preoperative CT scan of all 22 patients
were reviewed and all showed widespread features consis-
tent with pulmonary fibrosis.
Discussion
Patients with pulmonary fibrosis have a chronically progres-
sive diffuse fibrosing lung disease. The mean survival from
the onset of dyspnea is 3 to 6 years and an objective
response to treatment is seen in only 20% of the cases.7 The
diagnostic criteria have been recently refined and many
patients are now diagnosed on clinical and CT data alone,
although most cases, if biopsied, will show a histological
pattern of UIP. UIP is the most commonly seen of several
recognized patterns of interstitial pneumonia, recognition of
which in the context of pulmonary fibrosis provides impor-
tant prognostic data. NSIP is especially common in those
with associated connective tissue disorders.8
TABLE 2. Procedure specific mortality and incidence of
ARDS/ALI after pulmonary resections for NSCLC between
1991 and 2000
Group I
Pulmonary fibrosis
(n  24)
Group II
No pulmonary
fibrosis
(n  964) P value
Mean hospital stay (days) 17 9 .05
Range 2-127 2-96
Total deaths 4/24 (17) 30/964 (3.1) .01
Pneumonectomy 2/6 (33) 11/215 (5.1) .01
Lobectomy 2/17 (12) 18/695 (2.6) .01
Wedge resection 0/1 1/54 (2.0) NS
ARDS/ALI 5/24 (21) 36/964 (3.7) .01
Pneumonectomy 2/6 (33) 13/215 (6) .05
Lobectomy 3/17 (17) 22/695 (3.1) .05
Wedge resection 0/1 1/54 (1.8) NS
NS, Not significant.
Values in parentheses are percentages.
TABLE 3. Morbidity for all patients with pulmonary fibrosis
following resection for NSCLC
Chest infection (antibiotics and positive
putum culture)
13/24 (54)
Prolonged airleak (2 weeks) 7/24 (29)
ARDS/ALI 5/24 (21)
Cardiac event (myocardial infarction,
dysrhythmia)
6/24 (25)
Neurological event (stroke, transient ischemic attack) 2/24 (8)
Renal failure (need for renal replacement
therapy)
3/24 (13)
Data expressed with the total number of operations as the denominator.
Values in parentheses are percentages.
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Persistent chronic inflammation with repeated fibrosis
has been causally related to the etiology of a variety of
neoplasms in various organ systems, including hepatocellu-
lar carcinoma in hepatitis B or C,9 gastric cancer in chronic
Helicobacter pylori infection,10 colonic cancer in long-
standing ulcerative colitis,11 and pleural lymphoma in long-
standing tuberculosis-associated pyothorax.12 Using cohort
follow-up studies, a higher incidence of lung cancer has
been reported in patients with pulmonary fibrosis, with
some authors reporting an increased estimated risk of be-
tween 7 and 14 times despite adjusting for age, sex, and
cigarette smoking.1-2,13 However, other authors using a dif-
ferent approach, ie, death certificates registries, have dis-
puted these findings14,15 and evidence is currently conflict-
ing.16 Nevertheless, independent of relative risk, lung
cancer is often seen in patients with chronically established
pulmonary fibrosis,1 creating a significant surgical problem.
This study was undertaken to evaluate the risk and benefit
on a cohort of such patients.
Although the role of surgery in the management of
non-small cell lung cancer is well established,17,18 its value
in those patients with underlying pulmonary fibrosis and
consequently impaired pulmonary function is unclear.
This study shows that both the operative mortality and
morbidity for major pulmonary resection (lobectomy and
pneumonectomy) is significantly higher in patients with
pulmonary fibrosis. Furthermore, in a subgroup of patients
there is an accelerated phase of pulmonary fibrosis leading
to respiratory failure following pulmonary resection. None-
theless, the overall 3-year actuarial disease-free survival of
54% indicates that pulmonary resection for lung cancer in
patients with pulmonary fibrosis is justified if cases are
selected appropriately (Figure 1). Patients with pulmonary
fibrosis undergoing pulmonary resection, predictors of post-
operative ARDS/ALI included preoperative low KCO, low
DLCO, and high CPI. We did not identify any predictors of
long-term survival. When examined more specifically, a
prior histological diagnosis of pulmonary fibrosis was not
predictive of postoperative ARDS/ALI or late death. Pul-
monary fibrosis usually affects the lower lobes. However,
the coexisting emphysema preferentially affects the upper
lobes. In our study, there were a similar number of upper
and lower lobectomies and we were not able to explore the
relative importance of disease distribution in this series. A
larger cohort will be necessary to explore this further.
The important finding of features of pulmonary fibrosis
on the preoperative CT scan suggests that identification of
early radiological features of pulmonary fibrosis may be an
important marker of increased operative risk.
In this study, we have reported an increased incidence of
postoperative respiratory complications, especially ARDS/
ALI as defined by the North American and European Con-
sensus Committee.6 All 4 early postoperative deaths follow-
ing pulmonary resection were due to rapidly progressive
ARDS. We have previously reported the frequency of
ARDS/ALI to be 3.9% following pulmonary resection and
more importantly ARDS/ALI to be the cause of 72.5% of
the total mortality after pulmonary resection.19 Further-
more, the frequency of ARDS/ALI is directly related to the
extent of pulmonary resection, with the incidence of ARDS/
ALI being 3.7% after lobectomy and 6% after pneumonec-
tomy.19 In this paper, we have reported the overall incidence
of ARDS/ALI in patients with pulmonary fibrosis undergo-
ing resection for non-small cell lung cancer to be signifi-
cantly higher than the incidence of ARDS/ALI in patients
with no pulmonary fibrosis undergoing pulmonary resection
for non-small cell lung cancer during the same time period
(21% vs 3.7%). The extent of resection again appears to an
important factor, with the incidence of ARDS/ALI for pneu-
monectomy and lobectomy being 33% and 17%, respec-
tively. Another identifiable predictor of adverse outcome in
patients with pulmonary fibrosis undergoing pulmonary re-
section for non-small cell lung cancer was the extent of
pulmonary resection, the mortality for pneumonectomy be-
ing 33%, compared to 12% for lobectomy. Therefore, pneu-
monectomy should ideally be avoided in these patients.
However, as the extent of pulmonary resection can only be
reliably made intraoperatively after a thorough assessment
of intrathoracic lymph node status at thoracotomy,20 pneu-
monectomy may be unavoidable if complete resection is to
be achieved. If faced with this scenario, the surgeon may
have to opt out of a resection if pneumonectomy is the only
possible resection to achieve a complete resection.
The pathophysiology leading to the onset of acute lung
injury and ARDS/ALI following pulmonary resection re-
mains unclear and is likely to be multifactorial and possibly
Figure 1. Kaplan-Meier survival curve for all patients with pul-
monary fibrosis after pulmonary resection for NSCLC.
Kumar et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1325
G
TS
related to single lung ventilation.21,22 It may be that periods
of one-lung ventilation needs to be kept to a minimum or
avoided completely when undertaking pulmonary resection
in patients with pulmonary fibrosis.
In the decision to undertake pulmonary resection in pa-
tients with pulmonary fibrosis, a significant concern is the
impaired baseline respiratory function due to the underlying
pulmonary fibrosis, which will be further compounded by
surgical trauma and the adverse effects of general anesthe-
sia. In patients undergoing pulmonary resection, pulmonary
function tests have a significant role in the preoperative risk
stratification prior to pulmonary resection.23
In patients with pulmonary fibrosis, pulmonary function
tests are used to monitor disease progression and response
to treatment in patients, as well as provide an estimate of the
severity of disease. However, in pulmonary fibrosis, the
assessment of pulmonary function and the quantification of
disease severity are difficult, as it is often confounded by
coexisting emphysema. The lowest KCO in our series was
44% of predicted in a man who had right upper lobectomy
with an FEV1/FVC of 2.1/3.7  0.57 and most restrictive
FEV1/FVC was 1.4/1.6  0.88 with a KCO 63% of predicted
in a patient who underwent left upper lobectomy.
Noninvasive assessment of disease severity in pulmo-
nary fibrosis remains debatable. Pulmonary function tests
reflect the histological severity of the disease better than the
symptoms or chest radiography. Among routine indices, the
DLCO has the strongest correlation with the morphological
extent of the disease, both histologically24 and radiologi-
cally on CT.25 However, the interpretation of pulmonary
function tests is confounded by coexisting emphysema,
present in over 20% of the patients and resulting in spurious
preservation of lung volumes and depression of gas trans-
fer.26,27 Clinico-radiographic-pathologic (CRP) score is de-
rived to a great extent from a combination of 6 lung function
variables,27 however, the presence of emphysema is not
taken into account by the CRP score. Subsequently, the
CRP score has been modified to allow for coexisting em-
physema but the use of this index relies upon integration of
clinical and plain radiographical data.25 Recently, a CPI,
constructed against the morphological severity of the dis-
ease in order to calibrate the quantification of pulmonary
fibrosis, has been reported.5 CPI correlates more strongly
with the extent of disease on CT than any of the individual
pulmonary function tests and the better fit of CPI to the
extent of disease was ascribable to the correction for con-
founding effects of emphysema. CPI is also an excellent
predictor of prognosis in patients with the UIP form of
pulmonary fibrosis.5
However, little is known of the value of pulmonary
function tests in the context of surgery for patients with
pulmonary fibrosis and this study shows that KCO, DLCO, and
CPI are important preoperative predictors of adverse out-
come following pulmonary resection for non-small cell lung
cancer. In the study reported here, a preoperative CPI score
40 was associated with a 50% chance of developing
postoperative lung injury.
In this study, we also note that progressive pulmonary
fibrosis and respiratory failure were an important cause of
late death (5/7 late deaths). The cause for this rapidly
progressive pulmonary fibrosis following pulmonary resec-
tion leading to respiratory failure in patients with pulmonary
fibrosis is not known. However, this pattern of disease is
described as a terminal event in patients with pulmonary
fibrosis28 and it may be that surgical trauma and/or general
anesthesia accelerates the underlying disease process.
Kaplan-Meier survival analysis confirmed an actuarial sur-
vival at 36 months to be 54%. In assessing the longer-term
outlook after pulmonary resection for non-small cell lung
cancer, the importance of lymph node status and stage of the
lung cancer is well recognized. There were inadequate num-
bers of patients to make any meaningful assessment of
lymph node status on survival in this cohort of patients.
Eight of 24 (33%) of the resections were found to have pN1
or pN2 disease. While looking at the survival figures, it is
noteworthy that only 2 of 7 late deaths died of metastatic
lung cancer. The other 5 deaths were secondary to progres-
sive pulmonary fibrosis and respiratory failure with a mean
postoperative survival of only 14 months (range, 3 months
to 3 years). However, this is likely that this reflects death
due to progressive pulmonary fibrosis occurring before the
clinical manifestation of recurrent or metastatic disease.
We acknowledge that the case series reported here only
involves 22 patients with pulmonary fibrosis and as such
suffers from the criticisms leveled at all small case series.
Indeed, type II errors are theoretically possible when ana-
lyzing such small groups. However, as there were no mar-
ginal nonsignificant trends, this makes the possibility of
type II errors remote when looking at the results of predic-
tors of ARDS following surgery.
In conclusion, we report a significantly higher operative
risk (morbidity and mortality) associated with pulmonary
resection for non-small cell lung cancer in patients with
pulmonary fibrosis. Although knowledge of preexisting pul-
monary fibrosis prior to resection was not an important
factor in predicting the outcome, the presence of features
suggestive of pulmonary fibrosis on the preoperative CT
scan should be taken as an important marker for increased
operative risk. KCO, DLCO, and CPI are important prognostic
indicators. Outcome following pneumonectomy is poor.
Following pulmonary resection, there is an accelerated
phase of pulmonary fibrosis in some patients. Medium-term
outlook for the survivors is favorable and, therefore, pul-
monary resection for non-small cell lung cancer in patients
with pulmonary fibrosis is justifiable in selected cases.
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